What are the side effects of vaginal estrogen?
Low-dose vaginal estrogen is well tolerated. In placebo-controlled trials it was not associated with more adverse events than placebo, and most of what women notice are practical annoyances, like mess or discharge, rather than medical problems.
This page is about low-dose vaginal estrogen, the local form used for genitourinary syndrome of menopause (GSM), sometimes still called vaginal atrophy. It is not the same as systemic hormone therapy, and that difference explains almost every safety answer below.
What the trials actually found
A systematic review of 44 studies, including 14 placebo-controlled trials in more than 4,000 women, found no overall difference in adverse events between vaginal estrogen and placebo. Serum estradiol stayed within the normal postmenopausal range. That same review found the various formulations, creams, tablets, and rings, had no clinically significant difference in safety, so switching products for comfort does not cost you anything on safety. A later randomized trial of the 10-microgram estradiol tablet reached the same conclusions: the few side effects reported, such as a vaginal yeast infection, occurred at rates no different from placebo. When women ask what the side effects are, the honest answer is that in controlled studies they are hard to separate from the ordinary background rate of complaints in women taking a placebo.
The complaints that are actually common
The problems women report are usually about using the product, not about harm from the hormone. Creams can be messy and inconvenient. Vaginal discharge is the most commonly reported side effect in trials, noted by roughly 6 percent of users in one review. These practical issues, along with worry about long-term safety, are the usual reasons women stop, and a large share discontinue within the first few months. If mess or discharge is the problem, the fix is often a change of formulation rather than quitting. A tablet, an insert, or a ring gives a fixed dose without the mess of a cream.
Weight gain
Weight gain has not been shown to be a side effect of low-dose vaginal estrogen. The controlled trials did not find more adverse events on vaginal estrogen than on placebo, and weight change is not among the effects the evidence supports. The data simply do not point to weight as something low-dose vaginal estrogen does.
What about the boxed warning?
For years, every estrogen product carried an FDA boxed warning listing serious risks: heart disease, stroke, blood clots, dementia, and breast and endometrial cancer. Those risks came from studies of systemic hormone therapy. With low-dose vaginal estrogen, systemic absorption is minimal, and the 2020 North American Menopause Society position statement judged these labeled risks highly unlikely at vaginal doses. The FDA has since agreed: after reviewing the evidence, it began removing the boxed-warning statements on cardiovascular disease, breast cancer, and probable dementia in November 2025 and approved the first updated labels, topical vaginal estrogen among them, in February 2026.
Bleeding is the one thing to report
There is one symptom that should never be brushed aside. Any bleeding or spotting after menopause should be evaluated, whether or not you use vaginal estrogen. That usually means a pelvic ultrasound and sometimes an endometrial biopsy. Vaginal estrogen does not change that rule.
References
- Rahn DD, Carberry C, Sanses TV, et al. Vaginal estrogen for genitourinary syndrome of menopause: a systematic review. Obstetrics & Gynecology. 2014. doi:10.1097/AOG.0000000000000526
- Faubion SS, Sood R, Kapoor E. Genitourinary syndrome of menopause: management strategies for the clinician. Mayo Clinic Proceedings. 2017. doi:10.1016/j.mayocp.2017.08.019
- Faubion SS, Kingsberg SA, Clark AL, et al. The 2020 genitourinary syndrome of menopause position statement of The North American Menopause Society. Menopause. 2020. doi:10.1097/GME.0000000000001609
- Mitchell CM, Reed SD, Diem S, et al. Efficacy of vaginal estradiol or vaginal moisturizer vs placebo for treating postmenopausal vulvovaginal symptoms: a randomized clinical trial. JAMA Internal Medicine. 2018. doi:10.1001/jamainternmed.2018.0116
- U.S. Food and Drug Administration. FDA Approves Labeling Changes to Menopausal Hormone Therapy Products. FDA News Release. February 12, 2026. fda.gov
← Learn more about Vaginal Estrogen